Trump administration

Senate testimony on FY26 appropriations for HIV and hepatitis

As a nation, we are able to advance efforts to end the HIV and viral hepatitis epidemics. We possess proven prevention tools, including pre-exposure prophylaxis medication (PrEP), and effective treatments. We urge you to continue your historically strong commitment and leverage this pivotal moment to support the nation’s public health by comprehensively addressing these chronic diseases. Increased investment – and certainly not cuts – in surveillance, education, prevention, and care and treatment will lead to further progress in reducing HIV and viral hepatitis and allow us to continue to hold the promise of ending these epidemics.

read more

Questions for Dr. David J. Weldon on his nomination to become CDC director

As the Committee considers the nomination of David J. Welson, M.D. to serve as Director of the Centers for Disease Control and Prevention, the HIV+Hepatitis Policy Institute urges you to ensure the nominee will uphold a stalwart commitment to a comprehensive healthcare system that includes implementation of robust disease prevention efforts critical in making American healthier again and in ending the chronic diseases of HIV and hepatitis. These are suggested questions for Dr. Weldon concerning his support for 1) CDC HIV prevention programs instrumental in the Ending the HIV Epidemic Initiative (EHE), 2) increasing access to PrEP medications which prevent HIV transmission, and 3) CDC programs addressing viral hepatitis.

read more

Pin It on Pinterest